Rheumatology

Back to articles

Rituximab and tocilizumab are effective options for people with refractory RA

KEY POINT

Use of rituximab (Rituxan—Genentech, Biogen) and tocilizumab (Actemra—Genentech) resulted in greater improvements in outcomes compared with abatacept (Orencia—Bristol-Myers Squibb) in people with refractory rheumatoid arthritis (RA), according to results of a population-based prospective study published in BMJ.